Targeted deletions of cyclooxygenase-2 and atherogenesis in mice

Circulation

Volumn 121, Issue 24, 2010, Pages 2654-2660

  Hui, Yiqun ^a   Ricciotti, Emanuela ^a   Crichton, Irene ^b   Yu, Zhou ^a   Wang, Dairong ^a   Stubbe, Jane ^a   Wang, Miao ^a   Puré, Ellen ^b   Fitzgerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

atherosclerosis; inflammation; prostaglandins

Indexed keywords

ACTIN; CD11B ANTIGEN; CD45 ANTIGEN; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; PROSTAGLANDIN; VIMENTIN;

ARTICLE; ATHEROGENESIS; CELL ISOLATION; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HYPERLIPIDEMIA; LEUKOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ATHEROSCLEROSIS; CELLS, CULTURED; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; PROSTAGLANDINS; RECEPTORS, LDL; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 77954084036     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.910687     Document Type: Article

References (44)

1. Smyth E, Burke A, FitzGerald GA. Lipid-derived autocoids. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2005:653-670.
2. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2005;108:15-23.
3. Grosser T, Yu Y, FitzGerald G. A. Emotion recollected in tranquility: lessons from the COX-2 saga. Ann Rev Med. 2010;61:17-33.
4. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclo-oxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391-1399.
5. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114:784-794.
6. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, FitzGerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954-1957.
7. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Puré E, Lawson JA, FitzGerald GA. Cyclooxygenases, thromboxane and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111:334-342.
8. Vardeh D, Wang D, Costigan M, Lazarus M, Saper CB, Woolf CJ, FitzGerald GA, Samad TA. COX-2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. J Clin Invest. 2009;119: 287-294.
9. Wang D, Patel VV, Ricciotti E, Zhou R, Levin MD, Gao E, Yu Z, Ferrari VA, Lu MM, Xu J, Zhang H, Hui Y, Cheng Y, Petrenko N, Yu Y, FitzGerald GA. Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci USA. 2009;106:7548-7552.
10. Li AC, Glass CK. The macrophage foam cell as a target for therapeutic intervention. Nat Med. 2002;8:1235-1242.
11. Wang M, Zukas AM, Hui Y, Ricciotti E, Puré E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA. 2006;103:14507-14512.
12. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
13. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, Morrow JD, Fazio S, Linton MF. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443-452.
14. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.
15. Gualde N, Harizi H. Prostanoids and their receptors that modulate dendritic cell-mediated immunity. Immunol Cell Biol. 2004;82:353-360.
16. Rocca B, FitzGerald GA. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol. 2002;2:603-630.
17. Rocca B, Spain LM, Ciabattoni G, Patrono C, FitzGerald GA. Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. J Immunol. 1999;162:4589-4597.
18. Rocca B, Spain LM, Pure E, Langenbach R, Patrono C, FitzGerald GA. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999;103:1469-1477.
19. Pablos JL, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ. Cy-clooxygenase-1 and-2 are expressed by human T cells. Clin Exp Immunol. 1999;115:86-90.
20. Xu L, Zhang L, Yi Y, Kang HK, Datta SK. Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med. 2004;10: 411-415.
21. Zhang L, Bertucci AM, Smith KA, Xu L, Datta SK. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxy-genase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus. Arthritis Rheum. 2007;56:4132-4141.
22. Yang P, Zhang Y, Ping L, Gao XM. Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: molecular mechanisms and therapeutic potential. Int Immunopharmacol. 2007;7: 1414-1421.
23. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM. FOXP3+CD4 + CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol. 2006;177:246-254.
24. Mori N, Inoue H, Yoshida T, Tanabe T, Yamamoto N. Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I. Int J Cancer. 2001;94:813-819.
25. Rivero M, Santiago B, Galindo M, Brehmer MT, Pablos JL. Cyclooxygenase-2 inhibition lacks immunomodulatory effects on T cells. Clin Exp Rheumatol. 2002;20:379-385.
26. 2 in mice and humans. J Biol Chem. 2008;283:1179-1188.
27. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-184.
28. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des. 2008;14:1225-1230.
29. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest. 2003;112:945-955.
30. Babaev VR, Bobryshev YV, Stenina OV, Tararak EM, Gabbiani G. Heterogeneity of smooth muscle cells in atheromatous plaque of human aorta. Am J Pathol. 1990;136:1031-1042.
31. Cuff CA, Kothapalli D, Azonobi I, Chun S, Zhang Y, Belkin R, Yeh C, Secreto A, Assoian RK, Rader DJ, Pure E. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest. 2001;108:1031-1040.
32. Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, O'Byrne KJ, Fitzgerald DJ, Pidgeon GP. COX-2-linked attenuation of hypoxiainduced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther. 2008;326:51-58.
33. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF, Chung SW, Schissel SL, Ingber DE, Mitsialis SA, Kourembanas S, Perrella MA. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008;117:2114-2122.
34. Rudic RD, Brinster D, Cheng Y, Fries S, Song WL, Austin S, Coffman TM, FitzGerald GA. COX-2 derived prostacyclin modulates vascular remodeling. Circ Res. 2005;96:1240-1247.
35. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the Cross Trial Safety Analysis. Circulation. 2008;117:2104-2113.
36. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921-927.
37. Cipollone F, Fazia M, Iezzi A, Ciabattoni G, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, De Luca M, Prontera C, Chiarelli F, Cuccurullo F, Mezzetti A. Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans [retracted in: Arterioscler Thromb Vasc Biol. 2008;28:e1]. Arterioscler Thromb Vasc Biol. 2004;24:1259-1265.
38. Couzin J. Massive trial of Celebrex seeks to settle safety concerns. Science. 2005;310:1890-1891.
39. Barry OP, Praticò D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet micropar-ticles. J Clin Invest. 1997;99:2118-2127.
40. Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, Di Battista JA. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem. 2001;276:31720-31731.
41. Narasimha AJ, Watanabe J, Ishikawa TO, Priceman SJ, Wu L, Herschman HR, Reddy ST. Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2010;30:260-268.
42. Kainulainen H, Rantala I, Collin P, Ruuska T, Päivärinne H, Halttunen T, Lindfors K, Kaukinen K, Mäki M. Blisters in the small intestinal mucosa of coeliac patients contain T cells positive for cyclooxygenase 2. Gut. 2002;50: 84-89.
43. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol. 2006;26:2421-2432.
44. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519.